XOMA Royalty Reports Strong Q1 2025 Results

Xoma Corp. ( (XOMA) ) has released its Q1 earnings. Here is a breakdown of the information Xoma Corp. presented to its investors.

XOMA Royalty Corporation is a biotechnology royalty aggregator that focuses on acquiring potential future economics from pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotech companies. The company aims to support biotech firms in advancing their drug candidates while benefiting from royalty and milestone payments.

In the first quarter of 2025, XOMA Royalty Corporation reported significant financial results and strategic developments. The company received $18 million in cash receipts, including $13.4 million from royalty receipts, and highlighted key advancements in its pipeline and business development activities.

The company’s financial performance showed a notable increase in total income and revenues, reaching $15.9 million compared to $1.5 million in the same period of 2024. This growth was driven by milestone payments and royalties from its collaborations with partners such as Day One Biopharmaceuticals, Ipsen, and Takeda. Additionally, XOMA Royalty acquired a royalty interest in Castle Creek Biosciences’ D-Fi (FCX-007) and sold unpartnered Kinnate assets, further strengthening its portfolio.

XOMA Royalty’s strategic focus on shareholder value was evident in its share repurchase activity and prudent cash deployment. The company’s net income for the quarter was $2.4 million, a significant turnaround from a net loss of $8.6 million in the previous year. With a robust pipeline and accelerating royalty receipts, XOMA Royalty is optimistic about achieving sustained cash flow generation.

Looking ahead, XOMA Royalty Corporation remains committed to leveraging its extensive portfolio of assets to generate substantial milestone and royalty proceeds. The company’s management believes that its strategic initiatives and partnerships will continue to drive growth and deliver value to shareholders.